Drugs / SMUP-IA-01
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04339504 | Apr 2020 → Dec 2025 | osteoarthritis, knee | Medipost Co Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04037345 | Oct 2019 → Nov 2020 | osteoarthritis, knee | Medipost Co Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06798727 | Mar 2023 → Mar 2027 expected | osteoarthritis, knee | Medipost Co Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05182034 | Feb 2022 → Oct 2023 | osteoarthritis, knee | Medipost Co Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SMUP-IA-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037345 ↗ |
| Modality | Cell therapy | “Human umbilical cord blood-derived mesenchymal stem cells” NCT04037345 ↗ |
| Route | Other | “A single knee administration” NCT04037345 ↗ |